FDA greenlights Pfizer’s ELREXFIO for advanced multiple myeloma treatment
Pfizer Inc. has earned accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, ELREXFIO (elranatamab-bcmm). This drug aims to treat adult patients diagnosed with relapsed or refractory multiple myeloma (RRMM) who have undergone at least four previous therapy lines, including essential treatments. Rooted in Promising Clinical Trials The endorsement stems […]
